2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 599

Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)
Abstract Number: 2060

Comparative Histologic and Molecular Analysis of Synovial Tissue in Early Treatment-Naïve Psoriatic and Rheumatoid Arthritis
Abstract Number: 2823

Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor
Abstract Number: 1615

Comparative Risk of Atrial Fibrillation and Cardiovascular Events between TNF-Inhibitors and Ustekinumab in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Abstract Number: 1534

Comparative Risk of Diabetes Mellitus in Rheumatoid Arthritis Patients Treated with Different Biologics- a Cohort Study
Abstract Number: L09

Comparative Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors: A Cohort Study of Rheumatoid Arthritis Patients
Abstract Number: 1375

Comparative Safety of Flavocoxid (Limbrel) Versus Nsaids Among Osteoarthritis Patients
Abstract Number: 1773

Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis Due to Behçet’s Disease. National Multicenter Study of 177 Cases
Abstract Number: 824

Comparing Childhood- Versus Adult-Onset Polyarteritis Nodosa
Abstract Number: 2581

Comparing Treatment Patterns of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
Abstract Number: 1285

Comparision of Urate Burden in Well and Poorly Controlled Gout Patients: A Dual-Energy CT Study
Abstract Number: 2754

Comparison between Tocilizumab Prescribed As Monotherapy Versus Combined with Conventional Immunosuppressant Agents in Giant Cell Arteritis Patients
Abstract Number: 1549

Comparison of Adverse Events and Survival of Treatment in Patients with Rheumatoid Arthritis Receiving Combined Treatment of Methotrexate and Leflunomide Versus Those Receiving Biological Therapy
Abstract Number: 2244

Comparison of an Interactive Voice Response (IVR) to Smart Phone App to Determine Patient Preference for Reporting Gout Flares
Abstract Number: 388

Comparison of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme Α Reductase and Anti-Signal Recognition Particle Necrotising Myopathies: A Single Centre Experience

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].